Tilray Q4 revenue rises 25% on the back of international medical cannabis
Tilray Q4 revenue rises 25% on the back of international medical cannabis
Overview
Canada-U.S. cannabis and beverage firm's fiscal Q4 revenue rose 25% yr/yr
Adjusted EPS for fiscal Q4 rose to $0.05 from $0.01 a year ago
Company posted a net loss in Q4, mainly due to non-cash charges
Outlook
Tilray expects fiscal 2027 adjusted EBITDA of $68 mln to $75 mln
Company anticipates annual revenue above $1 bln in fiscal 2027
Tilray says regulatory uncertainty persists in U.S. cannabis market
Result Drivers
INTERNATIONAL MEDICAL CANNABIS - Co said international medical cannabis revenue rose 34% for the year, driven by its European platform and pharmaceutical distribution network
BEVERAGE SEGMENT EXPANSION - BrewDog acquisition and expanded partnerships drove beverage revenue and gross profit higher in Q4, with management citing improved performance and stabilization
DISTRIBUTION GROWTH - Distribution net revenue and gross profit rose in Q4, reflecting expanded infrastructure and operating leverage
Company press release: ID:nGNXSqzsX
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue |
| $281.71 mln |
|
Q4 Loss Per Share |
| $0.43 |
|
Q4 Adjusted Net Income |
| $5.30 mln |
|
Q4 Net Loss |
| $37.93 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "hold"
Wall Street's median 12-month price target for Tilray Brands Inc is C$7.25, about 26.7% above its July 27 closing price of C$5.72
Reuters Recommended Reads
July 28 - Coca-Cola hails World Cup hydration breaks as it lifts annual forecasts
July 26 - Brown-Forman board says unsolicited Sazerac takeover proposal not actionable
July 28 - GSK Q2 sales beat analyst estimates on specialty medicines growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Tilray Brands
See all newsCannabis firm Tilray's Q1 revenue rises 82% on BrewDog acquisition
Brief: Tilray Brands Q1 Revenue USD 257.147 Million
Brief: 10 Barrel Expands Salty Sips Rtd Portfolio With New Blackberry Refresher
Tilray Q4 revenue rises 25% on the back of international medical cannabis
Brief: Tilray Brands Q4 Revenue USD 281.714 Million